Tags : Co-Development Agreement

M&A

Takeda signs a Co-Development Agreement with Molecular Templates for CD38-Targeted

Shots: Takeda will provide upfront of $30M and to pay royalties on commercialization. CD38-Targeted ETBs’ development cost will be shared equally between both the parties Molecular Templates will receive development, regulatory and commercial milestone payments of up to $632.5M if company exercise its co-development option, or $337.5M if it does not exercise or opts out […]Read More